1H-Dibenz(2,3:6,7)Oxepino(4,5-C)Pyrrole, 5-Chloro-2,3,3A,12B-Tetrahydro-2-Methyl-, Trans-

The compound designated trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole (CAS 65576-45-6) constitutes the free-base form of the atypical antipsychotic asenapine. Its molecular formula is C₁₇H₁₆ClNO, corresponding to a monoisotopic mass of 285.0920 Da, with a tetracyclic framework that fuses a dibenzo-oxepine ring to a pyrrolidine moiety through a trans ring junction at positions 3a and 12b. The molecule is synthesized and registered as a racemic mixture of the trans enantiomers; the (3aR,12bR) and (3aS,12bS) forms both exhibit high-affinity receptor antagonism, but only the racemic trans-isomer is employed in commercial drug product presentations. Crystalline free base exhibits a melting endotherm onset near 141–145 °C by differential scanning calorimetry at 10 K·min⁻¹ under nitrogen purge, with polymorphism screening under ICH Q6A confirming at least two anhydrous forms relevant to milling and formulation processing. In bulk powder handling, particle size reduction via air-jet milling to a D₉₀ of <15 µm is necessary for uniform content in sublingual dosage forms; however, size reduction below D₅₀ 5 µm increases triboelectric charging and reduces flowability through rotary tablet press feed frames operating above 40 rpm, as observed on Fette 3090i presses.

Physicochemical Specification and Compendial Alignment

Alignment with USP–NF and Ph.Eur. monographs for asenapine free base predicates the release of the trans isomer with limits on related substances defined by ICH Q3A thresholds. Routine lot-release testing on a Waters Acquity H-Class system with a C18 column (150 × 4.6 mm, 3.5 µm) and a mobile phase of 0.01 M phosphate buffer (pH 3.0) / acetonitrile (60:40 v/v) quantifies the trans peak at relative retention time 1.00. The cis diastereomer, typically arising from incomplete epimerization during the catalytic hydrogenation step, is resolved at a relative retention time of approximately 1.15 and is limited to ≤0.15% area. Residual palladium, used as a catalyst in the reductive cyclization of the dibenzo-oxepine precursor, is controlled to ≤10 ppm by ICP-MS according to USP <232>/<233>, a critical limit given the compound’s intended chronic administration.

Beyond chemical purity, the solid-state form is routinely verified by X-ray powder diffraction (XRPD) with a copper Kα source, comparing the pattern of the trans free base against the reference diffractogram published in the Ph.Eur. monograph. Peak positions at 2θ of 9.2°, 14.7°, 18.3°, and 24.6° must match within ±0.2°. Any deviation suggests conversion to a different polymorph or hydrate, which, although not observed to drastically alter dissolution rate in sublingual films, affects milling energy input and downstream blending uniformity.

Manufacturing environments operating under ICH Q7 GMP guidelines encounter a distinct processing constraint: the free base exhibits electrostatic adhesion to polycarbonate and stainless-steel surfaces at relative humidity below 20%. In dedicated containment suites for high-potency compounds, this necessitates periodic ionizing bar decontamination of blending V-shells, as static accumulation alters blend uniformity values measured by stratified sampling and NIR spectroscopy.

What Differentiates the Trans Configuration from Cis Diastereomers in Dopamine D₂ Occupancy?

The pharmacological consequence of the trans ring junction geometry is a near-complete loss of affinity for the D₂ receptor when the cis diastereomer is isolated. Published positional cloning and radioligand displacement studies ([³H]-spiperone in CHO cell membranes) show the cis-isomer exhibits a K_i exceeding 500 nM, while the trans racemate binds with K_i 1.3 ± 0.2 nM. This >300-fold difference underscores the necessity of rigorous diastereomeric purity control in the final API. In contrast to benzisoxazole antipsychotics like risperidone, where stereochemistry is absent, or to the enantiopure esketamine, the asenapine molecule relies on relative configuration at the ring junction to pre-organize the aromatic planes for hydrophobic pocket insertion.

The trans configuration also stabilizes the tetracyclic core against metabolic N-demethylation. In vitro human liver microsome incubations (HLM, 0.5 mg protein·mL⁻¹, NADPH-regenerating system) show the trans racemate has a metabolic half-life of ~24 min, whereas the cis diastereomer degrades with a t_½ of ~8 min, predominantly through CYP1A2-mediated oxidation. This stereochemical protection is an intrinsic advantage over the tricyclic dibenzoxepine scaffold of earlier antidepressants, which required extensive methyl substitution to slow CYP metabolism.

The data in Table 2 illustrate a characteristic signature: a very high 5-HT_2A/D₂ binding ratio (~22) that is pharmacologically correlated with reduced extrapyramidal symptom (EPS) liability at therapeutic doses. Olanzapine achieves a ratio of approximately 2.8, and haloperidol exhibits an inverse ratio (~0.016). This receptor profile directly informs the compound’s indication for schizophrenia and acute manic episodes, as therapeutic plasma concentrations of 2–5 ng·mL⁻¹ translate to striatal D₂ occupancy of 40–65% measured by [¹¹C]-raclopride PET, remaining below the ~78% threshold associated with motor side effects.

In bulk substance storage, exposure to relative humidity above 60% for periods exceeding 72 h at 25 °C results in the nucleation of a monohydrate form with increased particle agglomeration and a distinct morphology resembling needle clusters. This hydrate converts back only upon drying at 60 °C under vacuum for 8 h, and interim wet mass exhibits up to 2.3% water uptake. All handling in pharmaceutical compounding must therefore maintain RH <50% in weighing and sieving isolators, and double polybag packaging with a desiccant packet of silica gel or molecular sieve 13X is standard for international shipment.

When formulating sublingual tablets, oral disintegration time becomes the governing critical quality attribute. Direct compression blends of trans-asenapine free base with mannitol (Pearlitol 200SD) and crospovidone (Kollidon CL, 5% w/w) on a Piccola B-10 rotary press yield tablets with a hardness of 25–35 N and an in vitro disintegration time of 15–25 s in 5 mL artificial saliva at 37 °C. The compound’s inherent bitter taste, with a bitterness threshold below 10 µg·mL⁻¹, necessitates excipient strategies: a combination of sucralose (2%) and a mint flavour system reduces taste rejection scores in volunteer panels from a mean of 4.2 to 1.8 on a 5-point scale. The sublingual route is non-negotiable because the oral absolute bioavailability is less than 2% due to extensive first-pass glucuronidation via UGT1A4, contrasting with olanzapine which maintains ~60% oral bioavailability without such extreme route dependence.

When Tetrachloroethane Replaces Methylene Chloride in Immersion Stripping

As an API intermediate destined for finished dosage forms, trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole is often handled in solution during cleaning validation of multi-product equipment. Swab recovery studies following a 0.1 N methanolic HCl immersion stripping protocol demonstrate 91% ± 4% recovery from 316L stainless steel coupons with a surface roughness Ra of 0.8 µm. When methylene chloride is substituted by tetrachloroethane for environmental containment reasons, recovery decreases to 63% unless the coupon is pre-wetted with a 2% polysorbate 80 solution, likely due to reduced resin solvation of the free base. This solvent-switch limitation is absent for risperidone free base, which achieves >90% recovery with tetrachloroethane alone, reflecting the influence of the fused oxepine oxygen on solvation enthalpy.

Genotoxic impurity risk assessment under ICH M7 mandates control of two potential structurally alerting intermediates: the chloro-dibenz[b,f]oxepine precursor and the N-methylnitrosamine derivative that could form if nitrite residues encounter secondary amines during work-up. Liquid chromatography–tandem mass spectrometry (LC‑MS/MS) with a limit of quantitation of 0.5 ppm is performed on each pilot-plant batch, applying a N-nitroso-2-methyl-2H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole reference standard. In 17 consecutive commercial batches, nitrosamine content has remained below the 1.5 µg·day⁻¹ acceptable intake limit, historically without requiring nitrite scavenger spiking. This contrasts with certain sartan APIs, where pervasive nitrosamine formation prompted global regulatory recalls, highlighting the intrinsic low nitrosation propensity of the tertiary amine in the pyrrolidine ring.

The trans free base also serves as the starting point for the research and development of long-acting injectable (LAI) formulations. Esterification of the pyrrolidine nitrogen is precluded by the methyl substituent, so prodrug approaches have focused on the formation of palmitate or pamoate salts with low aqueous solubility (<0.1 mg·mL⁻¹ at pH 7.4) to achieve once-monthly release. In such systems, residual chloride content measured by ion chromatography must be reduced below 500 ppm to avoid ionic strength-mediated precipitation during wet-bead milling on a Netzsch MiniCer mill.